- Open Access
Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation
© Song et al; licensee BioMed Central Ltd. 2009
- Received: 29 May 2009
- Accepted: 20 October 2009
- Published: 20 October 2009
Establishing a large rodent model of brain metastasis that can be monitored using clinically relevant magnetic resonance imaging (MRI) techniques is challenging. Non-invasive imaging of brain metastasis in mice usually requires high field strength MR units and long imaging acquisition times. Using the brain seeking MDA-MB-231BR transfected with luciferase gene, a metastatic breast cancer brain tumor model was investigated in the nude rat. Serial MRI and bioluminescence imaging (BLI) was performed and findings were correlated with histology. Results demonstrated the utility of multimodality imaging in identifying unexpected sights of metastasis and monitoring the progression of disease in the nude rat.
Brain seeking breast cancer cells MDA-MB-231BR transfected with firefly luciferase (231BRL) were labeled with ferumoxides-protamine sulfate (FEPro) and 1-3 × 106 cells were intracardiac (IC) injected. MRI and BLI were performed up to 4 weeks to monitor the early breast cancer cell infiltration into the brain and formation of metastases. Rats were euthanized at different time points and the imaging findings were correlated with histological analysis to validate the presence of metastases in tissues.
Early metastasis of the FEPro labeled 231BRL were demonstrated onT2*-weighted MRI and BLI within 1 week post IC injection of cells. Micro-metastatic tumors were detected in the brain on T2-weighted MRI as early as 2 weeks post-injection in greater than 85% of rats. Unexpected skeletal metastases from the 231BRL cells were demonstrated and validated by multimodal imaging. Brain metastases were clearly visible on T2 weighted MRI by 3-4 weeks post infusion of 231BRL cells, however BLI did not demonstrate photon flux activity originating from the brain in all animals due to scattering of the photons from tumors.
A model of metastatic breast cancer in the nude rat was successfully developed and evaluated using multimodal imaging including MRI and BLI providing the ability to study the temporal and spatial distribution of metastases in the brain and skeleton.
- Brain Metastasis
- Prussian Blue
- Fast Field Echo
- Spinal Cord Metastasis
The most common tumors in the central nervous system are metastasis originating from lung and breast cancer [1, 2]. Brain metastasis occurs in 51% of breast cancer patients, with a median survival of 13 months despite the institution of early treatment [1, 3, 4]. Magnetic resonance imaging (MRI) is a sensitive diagnostic tool with high spatial resolution and excellent tissue contrast used to detect brain metastases in patients with breast cancer [5, 6] however, MRI alone cannot identify micro-metastases or track dormant malignant cells in the brain [4, 7, 8]. Yoneda et al derived the MDA-MB-231BR cell line (231BR) that is estrogen independent from metastatic ductal carcinoma [9, 10] and specifically homes to brain . Intracardiac (IC) injection of the 231BR cells in nude mice was reported to form metastases in the brain and therefore animal models based on this cell line have been used for this purpose [8, 12, 13]. Recently, the 231BR was transfected with enhanced green fluorescent protein (EGFP) and following IC injection in mice and metastases were detected brains by optical imaging and fluorescent microscopy . Heyn et al labeled 231BR-EGFP cells with fluorescent micron-sized superparamagnetic iron oxide (MPIO) particles, and injected these cells into nude mice .
Single MPIO labeled breast cancer cells appeared initially after IC injection in the mouse as dark or hypointense voxels in the brain parenchyma on T2* weighted MRI that subsequently developed into metastases over 4 weeks . Heyn et al reported that between 1-3% of the initially injected MPIO labeled cells remained in the brain to form the visible tumors on MRI . Some of the labeled 231BR-EGFP cells were considered "dormant" based on the persistence of the hypointense signal in the same location of the brain over 28 days. Fluorescent microscopy demonstrated the presence of 231BR-EGFP cancer cells located within the cerebral vasculature in approximately the same location as the hypointense voxels on MRI. However, imaging studies with the brain seeking 231BR-EGFP breast cancer cell line have only been performed of the brain and therefore possible metastases in other tissues were not observed .
The goal of this study was to develop a rat model of brain metastases using the brain seeking breast cancer cell line 231BR that could be monitored with a clinical 3 tesla MRI. The 231BR cells were used because several reports have indicated that this breast cancer cell line was brain seeking and metastases were observed only in the brain by non-invasive imaging and histology [11–13, 15]. The 231BR cells were stably transfected with firefly luciferase (231BRL) in order to determine the distribution of the breast cancer metastasis over time by bioluminescent imaging (BLI). The 231BRL cells were magnetically labeled with ferumoxides complexed with protamine sulfate [12–21] in order to monitor the early implantation of tumor cells in the brain and to determine the sensitivity of T2* weighted 3 tesla MRI to the labeled cells and the subsequent detection of multiple metastases. Most MR imaging studies of brain metastases have been performed in mice using high field strengths scanners (i.e., ≥ 7 tesla) because of the ability to obtain high spatial resolution and signal to noise as compared to images obtain using a clinical scanners [22, 23]. Moreover, we employed multimodality imaging to direct the pathological examination from the unexpected areas of breast metastases that occurred following the IC infusion of the brain seeking 231BR breast cancer cell line .
Tumor cell line
The 231BR breast cancer cell line  was transfected with the mammalian expression vector pGL3-control (Promega Corporation, Madison, WI) using effectene reagent (Qiagen, Germantown, MD) according to the manufacturer's protocol to tag the cells with the firefly luciferase gene for bioluminescent imaging. The cells were co-transfected with pcDNA3.1 containing a neomycin resistance gene for the selection of clonal populations of luciferase expressing cells. Forty-eight hours after transfection cells were incubated in growth media containing 800 μg/ml G418 (Invitrogen, Carlsbad, CA) and single clones selected after 4 weeks in culture. Luciferase expression was confirmed using the Steady-Glo Luciferase Assay System according to the manufacturer's protocol (Promega Corporation, Madison, WI). The clone with the highest expression was used in the experiments described herein for the BLI tumor detection system. The cell line was cultured with DMEM growth media containing 10% fetal bovine serum and 1% penicillin streptomycin antibiotics (Invitrogen, Carlsbad, CA) at 37°C in room air with 5% CO2.
Ferumoxides-Protamine Sulfate (FEPro) labeling of 231BRL cells
The 231BRL cells were labeled with the commercially available ferumoxides (Feridex IV®, 11.2 mg/ml, Bayer-Schering Pharmaceutical Inc, Wayne, NJ) contrast agent complexed to preservative free protamine sulfate (10 mg/ml, American Pharmaceuticals Partner, Schaumburg, IL) as previously described . 231BRL cells were cultured until they reached 90% confluence. Ferumoxides (FE) and protamine sulfate (Pro) were mixed in fresh serum free RPMI 1640 medium (Biosource, Camarillo, Ca) at concentration ratio of FE:Pro of 100 μg/ml:6 μg/ml of media. The cells were incubated for two hours followed by overnight incubation with complete media. Labeled cells were washed 3 times with 10 unit/ml of heparinized PBS and trypsinized. Determination of average iron concentration per cell was done using a variable-field relaxometer (Southwest Research Institute, San Antonio, TX) as previously described [12, 16, 24].
Cellular viability and proliferation
A trypan blue exclusion test was performed to determine the effect of FEPro labeling on the 231BRL cell viability. To determine the proliferation capacity of the FEPro labeled cells, MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) cell proliferation assay (CellTiter 96® AQueous One Solution, Promega, Madison, WI) was performed using the manufacturer's protocol.
All in vitro measurements were performed in triplicate.
Group A rats (n = 18)
Group B rats (n = 8)
Group C rats (n = 5)
Prior to infusion of cells
Day 0 IC injection
3 × 106 FEPro labeled 231BRL
106 FEPro labeled 231BRL
106 unlabeled 231BRL
MRI and BLI Euthanized 4 of 18 rats
MRI and BLI
MRI and BLI
MRI and BLI
MRI and BLI
MRI and BLI Euthanized 4 of 14 rats
MRI and BLI
MRI and BLI
MRI and BLI Euthanized 5 of 10 rats
MRI and BLI
MRI and BLI
MRI and BLI Euthanized 3 of 5 rats
MRI and BLI
MRI and BLI
MRI and BLI Euthanized all rats
MRI and BLI
MRI and BLI
- Euthanize 8 rats -
- Euthanize 5 rats -
MRI scanning was performed on a clinical 3 tesla MRI unit (Intera, Philips Medical System, Netherlands, B.V.) with using a solenoid 4 cm radiofrequency receive only coil (Philips Research Laboratories, Germany) for rat brain. Physiological monitoring was performed with SAII MRI compatible unit (Small Animal Instruments Inc., Stony Brook, NY). The MR pulse sequences were as follows: T2-weighted (T2w) turbo spin echo (TSE) sequence, repetition time (TR)/echo time (TE) = 3200/60 ms, turbo spin echo factor 12, number of average (NAV) 8, field of view (FOV) 50 mm, slice thickness 0.5 mm, matrix 224 × 256, reconstructed resolution 100 × 100 μm, slice number 25; and a T2* multi echo gradient sequence (T2*w), TR/effective TE = 4560/28 ms, 15 echos, flip angle 30°, NAV 2, FOV 50 mm, slice thickness 0.5 mm, matrix 176 × 256, reconstructed resolution 200 × 200 μm. For contrast enhanced MRI studies gadopentetate dimeglumine (GdDTPA, 0.5 M, Magnevist, Bayer Schering Pharmaceuticals, NJ) at a dose of 0.3 ml/kg was injected through lateral tail-vein. Pre and post GdDTPA enhanced 3D T1-weighted (T1w) fast field echo (FFE) sequence were performed with TR/TE = 35/4 ms, flip angle 35°, NAV 8, FOV 50 mm slice thickness 0.5 mm × 25 sections and matrix 224 × 256 with a reconstructed in plane resolution 100 × 100 μm. The total MRI scanning time was less than 50 minutes per rat. For Group 2 and 3 rats, hyperintense masses on T2 weighted images on pre-euthanasia scans were manually counted and matched to regions of the brain in order to determine the distribution of metastases.
MRI studies were also performed in Group 2 and 3 rats to validate the presence of photon flux activity detected on BLI along the spinal cord of the animals. Sagittal MRI was performed of the spine as follows: T2w with TSE 3200/60 msec, field of view 50 mm, 0.5 mm slice thickness, matrix 224 × 172 reconstructed to 100 × 100 μm in plane resolution and T1w contrast enhanced FFE with 35.4/4.2 msec and flip angle of 35° with a field of view 50 mm and 0.5 mm slice thickness matrix size 224 × 172 reconstructed to 100 × 100 μm in plane resolution.
Bioluminescence imaging was performed using IVIS™ 100 system and analyzed with Living Image® software (Xenogen, Alameda, CA). For in vitro studies, FEPro labeled and unlabeled 231BRL cells were prepared in a black 96 well plates (Corning Costar Company, Cambridge, MA) from 105 cells to 195 cells per well and D-luciferin Firefly (synthetic sodium salt monohydrate, Biosynth International, Inc, Naperville, IL) was added to each well at a concentration of 150 μg/ml. Total photon flux from each well was obtained over 1 minute and correlated to the numbers of cells per well. The in vivo BLI was performed following intraperitoneal injection of luciferin substrate at concentration of 150 mg/kg at 10-15 minutes following injection with a 3-minute acquisition time. The BLI photon flux in photons/sec/cm2/steradian was obtained and comparisons were made to the serially acquired images. The background photon flux was measured at the outside of the rat and was automatically subtracted.
The rats were euthanized with an overdose of pentobartital Sodium (Nembutal, 50 mg/ml, Ovation Pharmaceuticals Inc., Deerfield, IL) and were perfused with heparinzed saline and 4% paraformaldehyde for histological examination. Brain, spinal cord, lung, liver, spleen, kidney, lymph node, bone marrow, and tumors in decalcified long bone and spine were harvested from animals. Six-micron thick sections were obtained and stained with hematoxylin and eosin of brain and other organs that had photon flux activity on pre-terminal BLI. Histological sections were of the brain were obtained in approximately the same plane as MRI to allow for imaging pathological comparisons. Consecutive sections were obtained for immunohistochemistry. IgG anti-human cytokeratin antibody (AE1/AE3, DacoCytomation, Denmark) and mouse IgG Vectastain® Elite ABC Kit was used to detect the human breast cancer cells. Immunostaining kits were purchased from Vector laboratories (Vector Laboratories, Inc., Burlingame, CA). Sections were incubated with biotinylated secondary antibody for 30 min and enhanced with 3,3'-diaminobenzidine (DAB). Counterstaining was done with Vector® Hematoxylin QS. Consecutive sections were stained with Perl's reagent (Prussian blue) for the presence of iron and counterstained with nuclear fast red as previously described [17, 24, 25]. Approximately 5-10 consecutive histological sections of the brain and selected tissues were analyzed and photographed under light microscopy (BX50F, Olympus Optical Co., LTD., Japan) for each rat. The images were processed using Adobe Photoshop 7.0 (San Jose, CA).
In vitro study results were entered into standard spreadsheet software package and statistical significance was performed using two-tailed t test with P < 0.05. A regression analysis was performed to correlate cell number to the photon flux. All results are reported as the mean ± standard deviation.
Cell labeling and in vitro analysis
Prussian blue (PB) staining proved homogenous high efficient labelling of 231BRL cells with FEPro (Additional file 1A). There were no significant differences between FEPro labeled and unlabeled cells in Trypan blue viability (i.e., 97.9% ± 1.96 versus 98.8% ± 1.98,) or for proliferation capacity as measured by MTS assay (i.e., Absorbance 1.244 ± 0.13 versus 1.158 ± 0.23). The average (n = 3 samples) intracellular iron content of was 10.7 ± 1.9 pg/cell for FEPro labeled cells and 0.3 ± 0.03 pg/cell for unlabeled 231BRL cells. There was a correlation between the cell number and photon flux intensity in vitro (Additional file 1B). Bioluminescence photon flux intensity of the 231BRL cells was not affected by FEPro labeling over the range of cell numbers evaluated with a minimum detection limit of 195 cells (Additional file 1C).
In vivo imaging with histological correlation
T2w images between 2-4 weeks post IC injection of 231BRL revealed multiple metastases in the brain. The distribution of brain metastases in groups 2 and 3 rats by week 3-4 was similar to that observed in the group 1 animals on the imaging studies. The majority of hyperintense brain metastases on T2w were located in the cerebral cortex (100%), thalamus and hypothalamic regions (92%), hippocampus and pons/medulla (85%) and tumors were less commonly found (> 55%) in the olfactory bulb, cerebellum and midbrain regions.
Histological findings in metastases in the body
Distribution of metastatic tumor determined on histology and imaging
Day 1 (n = 4)
Day 3 (n = 4)
Week 1 (n = 5)
Week 2 (n = 3)
Week 3 (n = 1)
(n = 8)
(n = 5)
All rats had evidence of tumor cell infiltration in the lymph nodes with distortion of nodal architecture. Lung, liver and renal metastases were found in animals euthanized at later time points however mass lesions (> 200 μm) were rarely seen (Additional file 3). In the spleen, breast cancer cells were diffusely disseminated throughout red and white pulp but no discrete mass lesions were found.
The development of a relevant large rodent model of brain metastases that can be monitor using relevant non-invasive techniques is needed to investigate the early distribution pattern of tumors and translate the imaging approaches to the clinic . The major finding of this study was the documentation using multimodality imaging approach of the development of tumor metastases model in the nude rat using the brain seeking 231BRL cell line. Bioluminescent imaging and MRI demonstrated primarily brain and bone metastases from this brain seeking breast cancer cell line. The 231BR breast cancer cell line was chosen for this study since it reported only produced brain metastases [11–13, 15] and we wanted to determine if we could develop model in large rodent and possibly go on to use bioluminescent activity in the brain as an outcome measure for future treatment. The surprising finding was that all of the breast cancer 231BR cell lines resulted in bone metastasis that was not previously described and missed on pathological examination. The results of this study strongly indicate the need of noninvasive whole body imaging when developing a new animal model. Jenkins et al  reported that following the transfection of MDA-MB-231 cells with firefly luciferase, the pattern of metastases was altered compared to the parent cell line and resulted in tumors in bone, brain, liver, lungs, lymph nodes, and kidneys. In this study, the fluc gene transfected 231BR cells also caused bone metastases in a similar distribution as previously reported in mice . In addition, the distribution of brain metastases in the rat model was similar to previous report in mice injected with green fluorescent protein transfected 231BR cell line . Of note, we have IC infused 231BR or 231BRL cells into nude mice and have observed development of bone metastases on BLI and micro CT scan (Additional file 4). These results indicate that the introduction of fluc into the cell genome appears to have altered the propensity of selective metastases of the 231BR cells to just the brain. Differences in genotype expression of the 231BRL cells at the various metastatic sites would be impressive but highly unlikely or significant and would require gene chip analysis that is beyond scope of this work. The findings in this study support the importance of multimodal imaging in the development and evaluation of cell lines intended to model clinical disease or home to a specific target tissue.
In the current study, photon flux activity was not visible originating from the brain in 75% of the Group 1 rats between weeks 1 to 2 post IC injection of cells, even though metastases were detected over 80% of rats on histology and MRI. The region of interest analysis of the photon flux from the heads of the group 2 rats between day 3 and week 1 shows an abrupt decrease toward background level (Additional file 2). The decrease in photon flux intensity in the rat brain between day 3 and week 1 post IC injection may be attributed to a change in pigmentation of the hair and skin of the animals , tumor cells being cleared from brain vasculature, areas of tumor hypoxia or poor delivery of luciferin to the tumors. Although the measured photon flux intensity from the brain region at week 3 is elevated compared to day 1 post infusion of 231BRL cells (Additional file 2), brain metastases detected on T2w images were not always present on BLI (Figure 3). Extrapolation from the in vitro photon flux activity versus numbers of the 231BRL cells injected (Additional file 1) would estimate that approximately 8.5% of the initially IC injected 106 tumor cells were located in the head on day 2. Between day 3 and week 1, the photon flux decreased and was estimated to be approximately 0.6% of the cells that remained or survived in the rat brain ultimately going on to form metastases. Heyn et al , reported that between 1-3% of the initially injected MPIO labeled cells remained in the mouse brain and went on to form the metastases at 4 weeks post infusion of cells. The difference between these two studies probably can be contributed to the size of the animals, the fluorescent versus luminescent labels in breast cancer cells and the in vivo optical imaging devices used and that MPIO are not metabolized in cells as compared to ferumoxides that dissolves in endosomes [29, 30]
The disappearance of hypointense voxels (i.e., voxels becoming isointense to surrounding brain) on the T2*w images by week 1 post IC injection of cells can be due to multiple factors including dilution of the FEPro label in rapidly proliferating cells , iron metabolism [29, 31] and/or the cells became apoptotic or died and were cleared from the vasculature before marginating into the parenchyma. Prussian blue stain of the brain revealed rare cells with intracellular iron in the cortex of 50% and 62.5% of group 1 and 2 rats euthanized at 2-4 weeks, respectively. The small numbers of PB positive cells were not detected using T2* weighted images probably because of the spatial resolution and image contrast (Figure 4E). The finding of isolated PB positive cells on histology would suggest the need for quantitative imaging approaches such as T2* maps that can be possibly correlated to amount of iron present in the brain [32, 33]. Heyn et al  reported the detection of a single MPIO labeled breast cancer cells in the brains of mice with a modified clinical 1.5T MR scanner using acquired with a voxel size of 39 × 39 × 100 μm at 4 weeks post infusion of cells. The apparent difference in being able to detect single dormant breast cancer cells at > 1 week post infusion between the latter study and current study (voxel size 100 × 100 × 500 μm) maybe due to the increased susceptibility effect generated by the MPIO versus the SPIO nanoparticles, smaller voxel size produced by MRI hardware modification and the MPIOs are not metabolized by the cell. The combination of quantitative T2* MR imaging performed prior to and post infusion of magnetically labeled cell should provide investigators with the ability to detect subtle changes in T2* maps that would indicate the persistence of SPIO in cells in the brain  that may be used in cell therapy trials.
MRI and BLI provided serial non-invasive assessment of the formation of metastases over time in the same cohort of animals. In the current model, 84.6% of all the animals developed brain metastases in 4 weeks when 106 cells were administered in 6 week-old nude rats. The distribution of 231BRL metastases in the rat brain on MRI is similar that has recently been observed on histological examination of the mouse brain following IC injection of the 231BR-EGFP by Fitzgerald et al . In the current study, metastases in the olfactory bulb and cerebellum were not as common as observed in the mouse brain . This difference may be contributed to MRI inability to clearly delineate micro-metastases because of image contrast on T2w images. The intent of this study was to develop a model of breast cancer metastases in the rat brain using a cell line that had been shown to produce brain metastases that could be detected using a clinical 3 tesla MRI unit. BLI demonstrated that IC injection of this brain seeking fluc transfected 231BR breast cancer cell line resulted in the development of metastases in the skeleton. Follow-up high-resolution MRI studies of these areas confirmed the presence of metastatic breast cancer. By using this multimodality approach, spinal cord metastases were also detected by MRI (Figure 4B-C) that had previously not been identified in mouse model studies using the 231BR cell line [11, 14, 15]. Of note, spinal cord metastasis represents about 8.5% of CNS metastasis and affects 0.1 to 0.4% of cancer patients . The detection of spinal cord metastases by MRI underscores the importance on using multimodality imaging techniques to evaluate experimental models of metastatic disease.
In this study, serial BLI and MRI were used to track the temporal and spatial distribution of breast cancer from the 231BRL cell line and the formation of metastases in the rat brain. MRI detected brain metastases in the rat brain 2-4 weeks following the IC injection of 106 231BRL cells in this highly reproducible model and findings confirmed on histological examination. Multimodality imaging detected the presence of metastases in the brain and spinal cord, bone and other internal organs during the disease course demonstrating the important role of in vivo imaging in the development of an experimental model. This rat model and non-invasive clinically relevant MRI techniques and BLI should be useful for the development of novel targeted drug, cellular and molecular therapies for the treatment of metastatic breast cancer.
This work was supported by the Intramural Research Program of the Clinical Center at the National Institutes of Health. We would also like to acknowledge Philips Medical Systems as part of a cooperative research and development agreement for providing the radiofrequency coil.
- DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR: The natural history of breast cancer patients with brain metastases. Cancer. 1979, 44: 1913-1918. 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Patchell RA: The management of brain metastases. Cancer Treat Rev. 2003, 29: 533-540. 10.1016/S0305-7372(03)00105-1.View ArticlePubMedGoogle Scholar
- Melisko ME, Kunwar S, Prados M, Berger MS, Park JW: Brain metastases of breast cancer. Expert Rev Anticancer Ther. 2005, 5: 253-268. 10.1586/14737126.96.36.199.View ArticlePubMedGoogle Scholar
- Mystakidou K, Boviatsis EJ, Kouyialis AT, Voumvourakis K, Kouloulias V, Kouvaris J, Vlahos L: Silent radiological imaging time in patients with brain metastasis. Clin Neurol Neurosurg. 2004, 106: 300-304. 10.1016/j.clineuro.2004.01.005.View ArticlePubMedGoogle Scholar
- Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ: The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol. 1995, 16: 373-380.PubMedGoogle Scholar
- Sze G, Milano E, Johnson C, Heier L: Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol. 1990, 11: 785-791.PubMedGoogle Scholar
- Aragon-Ching JB, Zujewski JA: CNS metastasis: an old problem in a new guise. Clin Cancer Res. 2007, 13: 1644-1647. 10.1158/1078-0432.CCR-07-0096.View ArticlePubMedGoogle Scholar
- Sharma M, Abraham J: CNS metastasis in primary breast cancer. Expert Rev Anticancer Ther. 2007, 7: 1561-1566. 10.1586/14737188.8.131.521.View ArticlePubMedGoogle Scholar
- Cailleau R, Young R, Olive M, Reeves WJ: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974, 53: 661-674.PubMedGoogle Scholar
- Rose DP, Connolly JM, Liu XH: Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. Cancer Res. 1994, 54: 6557-6562.PubMedGoogle Scholar
- Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R: A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res. 2001, 16: 1486-1495. 10.1359/jbmr.2001.16.8.1486.View ArticlePubMedGoogle Scholar
- Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, Vega-Valle E, Weil RJ, Stark AM, Vortmeyer AO, Steeg PS: Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008, 25: 799-810. 10.1007/s10585-008-9193-z.PubMed CentralView ArticlePubMedGoogle Scholar
- Simoes RV, Martinez-Aranda A, Martin B, Cerdan S, Sierra A, Arus C: Preliminary characterization of an experimental breast cancer cells brain metastasis mouse model by MRI/MRS. MAGMA. 2008, 21: 237-249. 10.1007/s10334-008-0114-6.View ArticlePubMedGoogle Scholar
- Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D: Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67: 4190-4198. 10.1158/0008-5472.CAN-06-3316.View ArticlePubMedGoogle Scholar
- Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, Mikulis DJ, Palmieri D, Bronder JL, Steeg PS: In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med. 2006, 56: 1001-1010. 10.1002/mrm.21029.View ArticlePubMedGoogle Scholar
- Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA: Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation. 2003, 76: 1123-1130. 10.1097/01.TP.0000089237.39220.83.View ArticlePubMedGoogle Scholar
- Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, Frank JA: Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology. 2003, 229: 838-846. 10.1148/radiol.2293021215.View ArticlePubMedGoogle Scholar
- Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, Read EJ, Frank JA: Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood. 2004, 104: 1217-1223. 10.1182/blood-2004-02-0655.View ArticlePubMedGoogle Scholar
- Bulte JW, Kraitchman DL: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004, 17: 484-499. 10.1002/nbm.924.View ArticlePubMedGoogle Scholar
- Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S, Rosenbrock H, Keller U, Heinzmann U, Rummeny EJ: Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology. 2003, 228: 760-767. 10.1148/radiol.2283020322.View ArticlePubMedGoogle Scholar
- Frank JA, Anderson SA, Kalsih H, Jordan EK, Lewis BK, Yocum GT, Arbab AS: Methods for magnetically labeling stem and other cells for detection by in vivo magnetic resonance imaging. Cytotherapy. 2004, 6: 621-625.View ArticlePubMedGoogle Scholar
- Anderson SA, Frank JA: MRI of mouse models of neurological disorders. NMR Biomed. 2007, 20: 200-215. 10.1002/nbm.1167.View ArticlePubMedGoogle Scholar
- Raman V, Pathak AP, Glunde K, Artemov D, Bhujwalla ZM: Magnetic resonance imaging and spectroscopy of transgenic models of cancer. NMR Biomed. 2007, 20: 186-199. 10.1002/nbm.1136.View ArticlePubMedGoogle Scholar
- Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM: Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 2001, 19: 1141-1147. 10.1038/nbt1201-1141.View ArticlePubMedGoogle Scholar
- Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, Bryant LH, Bulte JW: Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003, 228: 480-487. 10.1148/radiol.2281020638.View ArticlePubMedGoogle Scholar
- Levy LM, Di Chiro G, Brooks RA, Dwyer AJ, Wener L, Frank J: Spinal cord artifacts from truncation errors during MR imaging. Radiology. 1988, 166: 479-483.View ArticlePubMedGoogle Scholar
- Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T: Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res. 2005, 7: R444-454. 10.1186/bcr1026.PubMed CentralView ArticlePubMedGoogle Scholar
- Strain Chracteristics of Nude Rat. [http://sierrabiomedical.com/flex_content_area/documents/rm_rm_d_nude_rat1.pdf]
- Arbab AS, Wilson LB, Ashari P, Jordan EK, Lewis BK, Frank JA: A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed. 2005, 18: 383-389. 10.1002/nbm.970.View ArticlePubMedGoogle Scholar
- Burch S, Bisland SK, Wilson BC, Whyne C, Yee AJ: Multimodality imaging for vertebral metastases in a rat osteolytic model. Clinical Orthopaedics and Related Research. 2007, 230-236. 10.1097/01.blo.0000238787.44349.eb.Google Scholar
- Pawelczyk E, Arbab AS, Pandit S, Hu E, Frank JA: Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed. 2006, 19: 581-592. 10.1002/nbm.1038.View ArticlePubMedGoogle Scholar
- Kuhlpeter R, Dahnke H, Matuszewski L, Persigehl T, von Wallbrunn A, Allkemper T, Heindel WL, Schaeffter T, Bremer C: R2 and R2* mapping for sensing cell-bound superparamagnetic nanoparticles: in vitro and murine in vivo testing. Radiology. 2007, 245: 449-457. 10.1148/radiol.2451061345.View ArticlePubMedGoogle Scholar
- Rad AM, Arbab AS, Iskander AS, Jiang Q, Soltanian-Zadeh H: Quantification of superparamagnetic iron oxide (SPIO)-labeled cells using MRI. J Magn Reson Imaging. 2007, 26: 366-374. 10.1002/jmri.20978.PubMed CentralView ArticlePubMedGoogle Scholar
- Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster PJ: In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med. 2006, 55: 23-29. 10.1002/mrm.20747.View ArticlePubMedGoogle Scholar
- Song H-T, Lewis BK, Liu W, Jordan EK, Klaunberg B, Despress D, Palmieri D, Frank JA: Quantitative measurement of cerebral metastatic tumor burden of breast cancer cells in a nude rat model using T2* map histograms with bioluminescence imaging correlation. Joint Annual Meeting ISMRM-ESMRMB; 19-25 May; Berlin. 2007, 196-197.Google Scholar
- Lee SS, Kim MK, Sym SJ, Kim SW, Kim WK, Kim SB, Ahn JH: Intramedullary spinal cord metastases: a single-institution experience. J Neurooncol. 2007, 84: 85-89. 10.1007/s11060-007-9345-z.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.